Late-stage

Late-stage refers to the advanced phase of clinical drug development, typically Phase III trials, where a treatment is tested on large patient groups to confirm efficacy and monitor side effects before regulatory approval. It can also describe mature companies or startups that have progressed past the initial development and funding stages.

Why it’s in the news: It is in the news due to mixed results from major pharmaceutical trials, funding pressures, and deal-making activity in this critical business and research phase.

Latest on Late-stage

• STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
• STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies
• Late-stage funding squeeze; ISRO opens up space
• STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
• Late-stage deals revive in Southeast Asia, but early-stage founders remain under pressure
• STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

Connections

2 entities linked to Late-stage across the news graph.